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ABSTRACT
Small cell carcinoma of the urinary bladder is an extremely 
aggressive and rare tumor. Even though small cell carcinoma most 
commonly arises from the lungs there are several reports of small cell 
carcinoma in extrapulmonary sites. Due to its low frequency there is no 
well-established management for this disease. We report the case 
of a 61 year-old man with small cell carcinoma of the bladder who 
underwent radical cystectomy following neoadjuvant chemotherapy. 
We also reviewed the literature for the optimal treatment strategy.
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RESUMO
O carcinoma de células pequenas da bexiga urinária é um tumor 
extremamente agressivo e raro. Apesar desses tumores terem como 
sítio principal o pulmão, existem diversos relatos de carcinoma de 
pequenas células extrapulmonares. Pela baixa frequência, ainda 
não existe um tratamento bem estabelecido para essa neoplasia. 
Relatamos o caso de um homem de 61 anos de idade com carcinoma 
de células pequenas da bexiga urinária que foi submetido à 
quimioterapia neoadjuvante seguida de cistectomia radical. Fazemos 
ainda revisão na literatura em busca dos métodos de maior sucesso 
para o tratamento.
Descritores: Neoplasias da bexiga urinária/quimioterapia; Carcinoma 
de células pequenas/quimioterapia; Cistectomia/métodos; Relatos de 
casos
INTRODUCTION
Small cell carcinoma of the bladder is a very rare and 
aggressive histological subtype, and accounts for less 
than 1% of all bladder tumors.(1) Its management is 
challenging because it presents in the same way of 
other more frequent histological types, but with a 
high metastatic power. The diagnosis demands that 
the pathologist be suspicious and accurate in the 
analysis of the fragments of a transurethral bladder 
resection (TUR). Multimodal treatment, including radical 
cystectomy, chemotherapy and radiation therapy should 
be initiated as soon as possible for a chance of cure and 
to improve survival.(2,3) This kind of carcinoma presents 
metastasis and has a poor prognosis.
In the present article we report a case of a male 
patient with small cell carcinoma of the bladder and the 
development of the condition, and we aim to show the 
most current management of this tumor, which has no 
consensus for treatment in the international literature 
for being extremely rare. 
CASE REPORT
Patient JHC, male, 61 years old, came to the medical 
service with a complaint of hematuria and hypogastric 
pain for one year. The urinary tract ultrasound 
revealed an intravesical tumor, and he was submitted 
to bladder TUR, with a conclusive report for small cell 
carcinoma of the bladder. Faced with the diagnosis, 
the attending team chose to perform chemotherapy 
(received four sessions of cisplatin, gemcitabine and 
paclitaxel) (Figure 1).
When referred to our service, he was submitted to 
thorax and abdomen computerized tomography (CT) 
that showed a 6.2x6.0x5.5cm neoplasm on the left 
anterolateral wall of the bladder, suggesting invasion 
of the prostatic urethra. No lymph nodes were affected 
and there were no metastatic lesions at other sites. 
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The patent was then submitted to radical cystectomy, 
with a Bricker ileal derivation procedure, performed 
uneventfully, lasting 5 hours, with no need for blood 
transfusion. It is important to underscore that the 
time between the last chemotherapy and surgery was 2 
months.
The pathology report of the surgical specimen proved 
small cell carcinoma of the bladder with extravesical 
extension, perineural and vascular infiltration, and one 
lymph node affected (left obturator) out of 16 dissected. 
Free margins. Final staging T3bN1. 
During the post-operative period, the patient had 
pneumonia, was on antibiotics and was discharged 29 
days after surgery. There were no surgical events. He 
was referred to oncology to discuss adjuvant therapy 
which was not initiated, because the patient died 4 
months after surgery due to pulmonary thromboembolism 
(Figure 2). DISCUSSION
The first report of small cell carcinoma of the bladder was 
made in 1981 by Cramer et al. Since then, approximately 
600 cases were registered in the international literature.(4) 
It is characterized by its high aggressiveness and poor 
prognosis, and by the development of metastic disease 
in about 67% of patients.(3)
The small cell carcinoma of the bladder usually affects 
individuals of the same age, sex and presents the same 
symptoms and morphology of urothelial carcinoma. 
That is why it is a diagnostic challenge, depending only 
on the skills of the pathologist to differentiate it from 
urothelial carcinoma, which beside the factors already 
mentioned, has the same radiological aspect of small 
cell carcinoma of the bladder. There is no consensus 
as to treatment, because it is an uncommon condition. 
Thus, recommendations are based on retrospective 
studies, reports of individual cases, and protocols for 
small cell lung carcinoma.
Frequently, it presents with mixed histology.(5) 
Molecular studies show a common origin for small cell 
carcinoma of the bladder and urothelial carcinoma, when 
coexisting. However, management should be different, 
since it frequently presents metastases and has a poor 
prognosis. The pathological diagnosis of this kind of 
tumor is challenging and requires that the pathologist 
use immunohistochemical techniques for histological 
confirmation. As they are histologically identical, the 
World Health Organization standardization for small 
cell lung carcinoma is used. It comprises the following 
criteria for diagnosis of small cell carcinoma of the 
bladder: presence of group of small cells with scarce 
cytoplasm, few organelles, “salt and pepper” chromatin 
and high rate of mitoses (>10 mitoses/10 high power 
fields).(4)
Figure 1. Field with the presence of multiple mitoses, salt-and-pepper nuclei
Figure 2. General overview of the tumor
Figure 3. Marker CD-56 that characterizes neuroendocrine tumors
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On immunohistochemistry, these tumors express 
quite an amount of neurospecific enolase, chromogranin, 
synaptophysin and N-CAM (CD-56). The presence of 
one or more markers allows to establish the diagnosis 
of neuroendocrine tumor. Pathological staging is based 
on the consensus for urothelial carcinoma of the bladder 
(Figure 3).(4) 
Isolated therapies – whether TUR, partial cystectomy 
or radiation therapy – present benefit only in special 
cases of initial stage disease. Radical cystectomy is 
considered the best method to eliminate small cell 
carcinoma of the bladder completely, but it alone 
is believed to only change survival in stage I and II 
tumors.(3,6) Cheng et al. reviewed 64 cases and concluded 
that in patients submitted to radical surgery compared 
to those treated with combined treatment (whether 
only chemotherapy or radiation therapy or both as 
adjuvant), there was no increase in survival.(7) In contrast, 
chemotherapy adjuvant to radical cystectomy resulted 
in a favorable prognosis in other studies, including 
meta-analyses.(7,8)
Another alternative is neoadjuvant chemotherapy, 
recommended by the MD Anderson Cancer Center, 
which reported a 5-year disease free survival in 36% 
of the group submitted to radical cystectomy alone 
and of 78% in the group submitted to chemotherapy 
neoadjuvant to surgery.(9) Similarly, neo adjuvant radiation 
therapy has also shown itself efficient.
On the other hand, a Canadian group reported ten 
patients with pT3-T4, N0 lesions with chemotherapy, 
attaining complete remission in nine of them. The 2-year 
survival rate for this group was 70% and, 44% in 5 years.
(10) Another similar series reported four patients treated 
with chemotherapy followed by radiation therapy who 
survived 27 to 60 months. The advantage of this treatment 
is sparing the organ. Therefore, it is a less invasive 
treatment when compared to radical surgery, which is 
related to important rates of morbidity and mortality.(11)
Patients with metastatic disease should receive 
systematic chemotherapy, and the most common treatment 
regimens are platinum-based (cisplatin and etoposide, 
carboplatin, etoposide and cyclophosphamide) (Figure 2).(2)
CONCLUSION
Given the extremely aggressive and rare disease, little is 
known about pathogenesis and molecular biology. Data 
on the ideal approach for this kind of tumor are scarce, 
showing the importance of reporting such cases and, 
in this way, defining the best diagnostic and treatment 
methods.
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